Surgical Treatment of Refractory Open Angle Glaucoma
This study has been completed.
Sponsor:
iScience Interventional Corporation
Information provided by (Responsible Party):
iScience Interventional Corporation
ClinicalTrials.gov Identifier:
NCT01212861
First received: September 29, 2010
Last updated: September 11, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The primary objective of this study is to evaluate the safety, efficacy, and performance of the Suprachoroidal Dissection Instrument in creating a fistula between Schlemm's canal and the suprachoroidal space in refractory, open angle glaucoma subjects.
| Condition | Intervention |
|---|---|
|
Open Angle Glaucoma |
Device: Suprachoroidal Dissection Instrument (SDI) |
| Study Type: | Interventional |
| Study Design: | Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Surgical Treatment of Refractory Open Angle Glaucoma - A Prospective, Open-Label, Pilot Study |
Resource links provided by NLM:
Genetics Home Reference related topics:
early-onset glaucoma
MedlinePlus related topics:
Glaucoma
U.S. FDA Resources
Further study details as provided by iScience Interventional Corporation:
Primary Outcome Measures:
- Postoperative intraocular pressure, glaucoma medication usage, and visual acuity [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
| Enrollment: | 4 |
| Study Start Date: | August 2010 |
| Study Completion Date: | May 2012 |
| Primary Completion Date: | May 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: Suprachoroidal Dissection Instrument |
Device: Suprachoroidal Dissection Instrument (SDI)
The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
Other Name: SDI
|
Detailed Description:
The Suprachoroidal Dissection Instrument (SDI) is a manually operated surgical instrument designed for use within Schlemm's canal. The instrument can access Schlemm's canal through a small ab-externo dissection, allowing use in eyes with scarring due to previous surgery or trauma.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Available for up to 3 years follow-up.
- Diagnosed with primary open-angle, pseudoexfoliative, or pigmentary glaucoma or more than one glaucoma diagnosis of these types.
- Subject scheduled to undergo glaucoma surgery with the Suprachoroidal Dissection Instrument involving creation of fistula between Schlemm's canal and the suprachoroidal space without combined cataract surgery.
- Subject has failed at least one incisional glaucoma surgery (trabeculectomy, tube shunt, deep sclerectomy, viscocanalostomy, canaloplasty) or angle surgery (Trabectome) OR Is not a candidate for conventional glaucoma surgery due to reasons such as the presence of scleral buckle or compromised conjunctiva.
- Subject has IOP ≥ 16 mm Hg on maximally tolerated medications within the six week (-42 days) period prior to surgery.
- Visual field defect defined as mean deviation (MD) score worse than or equal to -10 dB on the Swedish Interactive Threshold Algorithm [SITA] Standard 24-2 Humphrey Analysis during the 6 month period prior to surgery. OR Subject has vertical cup-to-disk ratio ≥ 0.75 during the 6 month period prior to surgery.
Exclusion Criteria:
- Significant lens opacities or patient is candidate for cataract surgery during the duration of the study.
- The patient had developmental glaucoma or a secondary glaucoma including steroid-induced, uveitic, or neovascular glaucoma (with the exception of pigmentary and pseudoexfoliative glaucoma).
- The patient has narrow angle component possibly associated with glaucoma in the operative eye.
- The subject has angle recession in the operative eye.
- Significant ocular disease other than glaucoma affecting the assessment of visual function.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01212861
Locations
| United States, Texas | |
| Glaucoma Associates of Texas | |
| Dallas, Texas, United States, 75231 | |
Sponsors and Collaborators
iScience Interventional Corporation
Investigators
| Principal Investigator: | Ronald Fellman, MD | Glaucoma Associates of Texas |
More Information
No publications provided
| Responsible Party: | iScience Interventional Corporation |
| ClinicalTrials.gov Identifier: | NCT01212861 History of Changes |
| Other Study ID Numbers: | 060410 |
| Study First Received: | September 29, 2010 |
| Last Updated: | September 11, 2012 |
| Health Authority: | United States: Institutional Review Board |
Additional relevant MeSH terms:
|
Glaucoma Glaucoma, Open-Angle Ocular Hypertension Eye Diseases |
ClinicalTrials.gov processed this record on May 22, 2013